Some experts believe a technological tipping point is imminent, if not already here, but adoption of point-of-care MDx has ...

The company reported difficulties ahead for its immunodiagnostics business in China in the wake of changes in late April related to the country's Diagnosis-Related Groups (DRG) policy on hospital lab ...

Last week, readers were most interested in a story about Roche's blood-based Alzheimer's test getting CE marking.

The deal brings together Promega's Maxwell automated nucleic acid extraction system and Longhorn's viral molecular transport media.

The company raised its full-year revenue guidance slightly due to changing foreign exchange rates but lowered its full-year EPS guidance.

An assessment of the documentation for 30 over-the-counter diagnostic tests found none met the current regulatory standards.

The blood test is designed to detect the accumulation of amyloid protein deposits in the brain, a hallmark of Alzheimer's disease.

The firm posted before the market open on Tuesday results that beat expectations, and it raised its full-year revenue and earnings guidance.

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.

The Boston-based digital pathology firm's updated US Food and Drug Administration clearance will help it to quickly validate its software with new hardware combinations.

NEW YORK – The University of California, Los Angeles School of Dentistry and South Korean semiconductor firm Dongwoon Anatech said on Friday that they have inked a three-year agreement worth upward of ...